TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05737667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Readiness Intervention (YRI)
Description: The YRI is a culturally adapted group intervention that integrates common practice elements of cognitive behavioral and interpersonal therapies. The YRI's core treatment elements target improving emotion regulation skills, interpersonal functioning, and problem-solving skills. The YRI has 12 session that last about 90 minutes. The YRI will be delivered in schools by teachers receiving either mobile-based supervision or standard, in-person supervision.
Study: NCT04618705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Participants will start a smoking cessation program.
Study: NCT05078034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet Non-Invasive Ventilation (HNIV)
Description: HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Oxygen
Description: HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.
Study: NCT05475873

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Description: A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Description: A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
Study: NCT04884308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG TICE Vaccine
Description: Intradermal vaccination with BCG TICE

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG TICE Vaccine
Description: Intradermal vaccination with BCG TICE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG TICE Vaccine
Description: Intradermal vaccination with BCG TICE
Study: NCT05611892

Intervention type: COMBINATION_PRODUCT
Intervention: 18F-FDS PET/CT
Description: 20 millicurie (mCi) of 18F-FDS in adult patient age group and 2.5 mCi in children (age 12-18 years old) followed by a PET/CT scan.
Study: NCT05573737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: education about ubilical cord care
Study: NCT05737667

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Youth Readiness Intervention (YRI)
Description: The YRI is a culturally adapted group intervention that integrates common practice elements of cognitive behavioral and interpersonal therapies. The YRI's core treatment elements target improving emotion regulation skills, interpersonal functioning, and problem-solving skills. The YRI has 12 session that last about 90 minutes. The YRI will be delivered in schools by teachers receiving either mobile-based supervision or standard, in-person supervision.
Study: NCT05905640

Intervention type: OTHER
Group type: OTHER
Intervention: Method of PrEP delivery and consultation
Description: All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider.
Study: NCT05133804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Ritalin 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine
Description: Reboxetine 4mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Reboxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Ritalin
Study: NCT05504902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile coordinated reset
Description: The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with Advanced stage Parkinson's disease
Study: NCT06562179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci SP® Single-Port Robotic Surgical System
Description: The da Vinci SP® Surgical System is designed to enable the performance of surgical procedures using a minimally invasive single-port approach. The system consists of a Surgeon Console, a Vision Cart, and a Patient Cart and is used with a camera, instruments, and accessories.
Study: NCT05629728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: Sun-style Tai Chi (21 forms)
Study: NCT04546620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: Arm A patients will receive R-CHOP alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP + acalabrutinib
Description: Arm B patients will receive R-CHOP in combination with acalabrutinib.
Study: NCT06034483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise training
Description: * Pelvic floor muscle contraction will be verified with vaginal palpation and a progressive pelvic floor muscle training program will be given.~* In the pelvic floor muscle training program:~* Fast and slow pelvic floor muscle contractions will be taught,~* Training will begin with 3 sets of exercises per day, exercise compliance of individuals will be monitored in the controls to be made every 2 weeks, and the number of exercise sets will be increased by one set.~* 1 set of exercises: It will include 10 fast + 10 continuous (frequent-(3-10 sec) hold-release) contractions.~* Individuals will be tracked with exercise diaries.~* At the end of the 8th week, post-intervention evaluations will be made again.~* The exercise program will be completed with a total of 6 sets of exercises per day (60 fast and 60 slow per day).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient/individual education
Description: In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~* Explaining menopause and menopausal symptoms~* Defining the Genitourinary Syndrome of Menopause (MGS)~* The effect of MGS on sexual function cycle and sexual function,~* Conservative recommendations on MGS management~* Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient/individual education
Description: In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~* Explaining menopause and menopausal symptoms~* Defining the Genitourinary Syndrome of Menopause (MGS)~* The effect of MGS on sexual function cycle and sexual function,~* Conservative recommendations on MGS management~* Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month.
Study: NCT05889546

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Lung, liver, skin, subcutaneous metastases, and blood specimens may be collected via rapid autopsy within 10 hours of expiration.
Study: NCT05815394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-labeled NY108
Description: Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.
Study: NCT05853653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using dolls in breastfeeding education
Description: Using dolls in breastfeeding education
Study: NCT05621512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive sessions
Description: Preventive sessions between the pregnant employee, her manager and a midwife.
Study: NCT05363085

Intervention type: OTHER
Intervention: Mechanically ventilated neurosurgical patients
Description: Observational study where respiratory variables and intracranial pressure will be measured during mechanical ventilation and during specific respiratory manoeuvres. No intervention is planned.
Study: NCT04972981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-901
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-901
Description: Intravenous infusion
Study: NCT06058871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular messages
Description: The EMI-I messages will be delivered in sequence over three months. The content, frequency, and timing of the messages will be determined by participant preferences, as determined during the baseline evaluation, as personalisation is central to such cognitive and behavioural changes. The messages will mainly be text-based, but other forms such as videos will also be used, depending on the needs of the participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led real-time support messages (chat type)
Description: The nurse will initiate 10-15-minute chats via an online platform (e.g., WhatsApp) after all instant messages for each session have been delivered. The nurse will guide the participants to set goals for breastfeeding. Any anticipated barriers will be discussed. The participants can also initiate the chats. While there is no limit to the number of chat messages, nurse-led real-time support messages will be provided during working hours (i.e., 9 am-6 pm on weekdays).
Study: NCT05459220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410 Injection
Description: SHR0410 Injection（Low Dose）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410 Injection
Description: SHR0410 Injection（High Dose）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for SHR0410 Injection.
Study: NCT05474443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial gun with conventional therapy
Description: MYofascial gun was applied for the duration of 5 minutes over upper trapezius muscle. every week, on first two sessions frequency was set to 1-2 then for next two 3-4 and so on conventional therapy Hot Pack applied at the beginning of session for 10 minutes Muscle stretching of Upper Trapezius, Levator Scapulae and Pectoralis Major applied with holding time 20 seconds and 4 repetitions.~Cold pack was applied at the end of the session for few minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument Assisted Soft Tissue Mobilization with Conventional therapy
Description: Graston's tool was applied over upper trapezius muscle from its origin to insertion kept at the angle of 45 Conventional Therapy Hot pack 10mins Upper Trapezius, Levator scapule and Pectoralis major muscle stretching(20s hold and 4 reps) Cold pack for few minutes
Study: NCT04957940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: Intravenous fish-oil-based lipid (SMOF lipid 20%) (Fresenius Kabi, Bad Homburg, Germany) emulsion supplementation to standard enteral nutrition in a dose of 100 ml/day at a rate of 12.5 ml/h over 8 h daily for 5 days.
Study: NCT05624632

Intervention type: OTHER
Intervention: Remote cognitive testing
Description: Remote cognitive testing
Study: NCT05038514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musıc therapy
Description: After the prone position was given to the patients, according to the randomization table, the intervention group was given 30 minutes by the nurse. nature-based music therapy will be applied.
Study: NCT05140980

Intervention type: OTHER
Intervention: Data collection
Description: evaluation of women's knowledge concerning sexuality
Study: NCT04957940

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Receive standard enteral nutrition plus 100 ml/day 0.9% normal saline at a rate 12.5 ml/h over 8 h for 5 days
Study: NCT05914259

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.
Study: NCT06070571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yarrow and moringa mixture
Description: yarrow and moringa mixture nano particles loaded on buccal film

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yarrow and moringa mixture
Description: yarrow and moringa mixture nano particles loaded on buccal film
Study: NCT04149275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Treatment with oral Cabozantinib once daily
Study: NCT05914259

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.
Study: NCT06350500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Receive patient navigation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study: NCT05914259

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.

Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.
Study: NCT01053065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin - Cholestyramine - Sitosterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin - Cholestyramine - Sitosterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin - Cholestyramine - Sitosterol
Study: NCT05878080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
Study: NCT05946486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunomodulatory treatment by rituximab
Description: 1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)
Study: NCT05177107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phage Therapy
Description: Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
Study: NCT06454968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib, obinutuzumab, lenalidomide
Description: Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
Study: NCT05177107

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline)
Study: NCT04149275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV administration of Ipilimumab on 21 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
Study: NCT06301243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inactivity
Description: Low physical activity level prior to the exercise intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactivity
Description: Low physical activity level prior to the exercise intervention.
Study: NCT05542901

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Joint Position Sense Analysis
Description: The Xsens DOT Motion Capture System will be used to analyze joint position sense.
Study: NCT06355752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling of lumbar iliocostalis muscle
Description: Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. Ten incisions will be made in the muscle.~The head will rest comfortably on a pillow

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling lumbar iliocostalis muscle
Description: Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. The placebo needle will move 10 times imitating the real procedure.~The head will rest comfortably on a pillow
Study: NCT06511245

Intervention type: OTHER
Group type: OTHER
Intervention: Randomisation
Description: Technique assigned through randomization

Intervention type: OTHER
Group type: OTHER
Intervention: Randomisation
Description: Technique assigned through randomization
Study: NCT05352776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtaCor EV-ICD Lead
Description: Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
Study: NCT04765072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Patient Navigation Intervention
Description: Patient navigator assistance for navigating the healthcare system and locating and utilizing beneficial resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Survivorship Visit Intervention
Description: Individualized survivorship care plan
Study: NCT06561191

Intervention type: OTHER
Group type: OTHER
Intervention: Hemodialysis mode, dialyzer type
Description: Change of hemodialysis mode and dialyzer type
Study: NCT06561061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: Dispersible (20 mg) tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispersible tablet
Study: NCT03675633

Intervention type: DIAGNOSTIC_TEST
Intervention: FEUrea
Description: FEUrea in decompansated liver cirrhosis
Study: NCT06219031

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06090721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT310
Description: Topical Powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Topical Powder
Study: NCT06446713

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image guided hybrid hyper-fractioned dose escalation with proton therapy
Description: Radiation: Image-guided hybrid hyper-fractioned dose escalation with proton therapy~The investigational radiation regime will be administered in a two-part schedule:~* The first 4 weeks (i.e. first 20 fractions) of the radiation treatment of the pathological tumor will be according to the conventional clinical standard with proton therapy: 20x 2 Gy to the CTV70 and 20 x 1.55 Gy to the CTV54.~* In week 4 (\~ fraction 16) GTV80 will be determined on conventional weekly CT and additional MR imaging (conventional clinical protocol). Only this adapted tumor volume, the so-called GTV80, will receive the dose escalation (i.e., 80.5 Gy).~* In the last 3 weeks (last 15 fractions) patients will be radiated twice per day (i.e. hyperfractionation). The GTV80, CTV70 and CTV54 will receive 1.55 Gy in the morning, and the GTV80 and CTV70 will receive additional dose in the afternoon.
Study: NCT05114512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAPTOR protocol: hybrid in-person + telehealth physical therapy services
Description: All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program.
Study: NCT05199038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide infusion for 2 days in patients with bleeding esophageal varices.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide infusion for 2 days in patients with bleeding esophageal varices.